- Home
- REBN vs EVAX Comparison
REBN vs EVAX Comparison
Compare REBN & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- EVAX
- Stock Information
- Founded
- REBN 2015
- EVAX 2008
- Country
- REBN United States
- EVAX Denmark
- Employees
- REBN N/A
- EVAX N/A
- Industry
- REBN Restaurants
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- REBN Consumer Discretionary
- EVAX Health Care
- Exchange
- REBN Nasdaq
- EVAX Nasdaq
- Market Cap
- REBN 8.6M
- EVAX 8.7M
- IPO Year
- REBN 2022
- EVAX 2021
- Fundamental
- Price
- REBN $1.80
- EVAX $1.06
- Analyst Decision
- REBN
- EVAX Strong Buy
- Analyst Count
- REBN 0
- EVAX 2
- Target Price
- REBN N/A
- EVAX $11.00
- AVG Volume (30 Days)
- REBN 107.6K
- EVAX 869.7K
- Earning Date
- REBN 11-19-2024
- EVAX 10-31-2024
- Dividend Yield
- REBN N/A
- EVAX N/A
- EPS Growth
- REBN N/A
- EVAX N/A
- EPS
- REBN N/A
- EVAX N/A
- Revenue
- REBN $5,502,528.00
- EVAX $3,295,000.00
- Revenue This Year
- REBN $185.18
- EVAX $4,845.21
- Revenue Next Year
- REBN $64.55
- EVAX $30.30
- P/E Ratio
- REBN N/A
- EVAX N/A
- Revenue Growth
- REBN 9.70
- EVAX N/A
- 52 Week Low
- REBN $0.92
- EVAX $0.84
- 52 Week High
- REBN $8.80
- EVAX $13.61
- Technical
- Relative Strength Index (RSI)
- REBN 64.22
- EVAX 37.33
- Support Level
- REBN $1.06
- EVAX $0.84
- Resistance Level
- REBN $1.97
- EVAX $0.96
- Average True Range (ATR)
- REBN 0.19
- EVAX 0.15
- MACD
- REBN 0.09
- EVAX 0.02
- Stochastic Oscillator
- REBN 81.32
- EVAX 38.80
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an innovative company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About EVAX Evaxion Biotech A/S
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.